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Background: Inadequate blood pressure control and poor adherence to treatment remain among the major
limitations in the management of hypertensive patients, particularly of those at high risk of cardiovascular events.
Preliminary evidence suggests that home blood pressure telemonitoring (HBPT) might help increasing the chance
of achieving blood pressure targets and improve patient’s therapeutic adherence. However, all these potential
advantages of HBPT have not yet been fully investigated.
(Continued on next page)* Correspondence: gianfranco.parati@unimib.it
1Department of Cardiology, IRCCS Ospedale San Luca, Istituto Auxologico
Italiano and Department of Clinical Medicine and Prevention, University of
Milano Bicocca, Milano, Italy
Full list of author information is available at the end of the article
© 2013 Parati et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Parati et al. Trials 2013, 14:22 Page 2 of 11
http://www.trialsjournal.com/content/14/1/22(Continued from previous page)
Methods/design: The purpose of this open label, parallel group, randomized, controlled study is to assess whether,
in patients with high cardiovascular risk (treated or untreated essential arterial hypertension - both in the office and
in ambulatory conditions over 24 h - and metabolic syndrome), long-term (48 weeks) blood pressure control is
more effective when based on HBPT and on the feedback to patients by their doctor between visits, or when
based exclusively on blood pressure determination during quarterly office visits (conventional management (CM)). A
total of 252 patients will be enrolled and randomized to usual care (n=84) or HBPT (n=168). The primary study
endpoint will be the rate of subjects achieving normal daytime ambulatory blood pressure targets (<135/85
mmHg) 24 weeks and 48 weeks after randomization. In addition, the study will assess the psychological
determinants of adherence and persistence to drug therapy, through specific psychological tests administered
during the course of the study. Other secondary study endpoints will be related to the impact of HBPT on
additional clinical and economic outcomes (number of additional medical visits, direct costs of patient
management, number of antihypertensive drugs prescribed, level of cardiovascular risk, degree of target organ
damage and rate of cardiovascular events, regression of the metabolic syndrome).
Discussion: The TELEBPMET Study will show whether HBPT is effective in improving blood pressure control and
related medical and economic outcomes in hypertensive patients with metabolic syndrome. It will also provide a
comprehensive understanding of the psychological determinants of medication adherence and blood pressure
control of these patients.
Trial registration: Clinical Trials.gov: NCT01541566
Keywords: Hypertension, Blood pressure, Home blood pressure telemonitoring, Adherence, Anxiety, Depression,
Personality traitsBackground
The prevalence of arterial hypertension in the European
population is estimated to approximate 20% [1]. Hyperten-
sion is one of the major risk factors for developing cardio-
vascular diseases such as heart failure, stroke, coronary
heart disease, and renal failure, and it is one of the most fre-
quent reasons for access to medical care [1,2]. Hypertension
is also often associated with other cardiovascular risk fac-
tors such as obesity, dyslipidemia, impaired glucose toler-
ance, or diabetes, which give rise to a condition known as
metabolic syndrome, affecting one-quarter of the popula-
tion and increasing by five- to six-fold cardiac morbidity
and mortality as compared to healthy individuals [3-6].
Although numerous studies have shown that antihyper-
tensive treatment may reduce cardiovascular risk and des-
pite availability of several valuable antihypertensive drug
options, today, no more than 30% of treated hypertensive
patients maintain a satisfactory blood pressure control [1,7].
This may be caused by many factors, among which poor
or complete lack of adherence to treatment prescriptions
have been reported to play a major role. Compliance to
therapy seems to be related to many factors including the
high number of pills to be taken daily, an excessive cost of
the available medications, the lack of motivation and poor
patient’s involvement in the management of this clinical
condition, the long wait in the doctor’s office, the absence
of symptoms, the inability of the patient to understand
the real long-term consequences of high blood pressure,and finally the psychological and personality traits of the
patients [8].
Different solutions may be adopted in order to improve
blood pressure control and patients’ adherence to therapy.
An effective organization for a better management of this
condition based on new technologies, through which the
efficacy of therapy can be monitored, could help patients
to get more involved in the daily care of their treatment,
and to better cooperate with the physician. One of the
methods used to obtain a better therapy adherence and
therefore a more effective blood pressure control is now
represented by self-measurement of blood pressure at home
by automatic electronic devices [9]. This method repre-
sents a valuable alternative to conventional blood pressure
measurement by physicians in their offices. Several studies
have shown that, compared to office blood pressure meas-
urement, self-measurement of blood pressure at home
allows a better control of blood pressure [10,11] and that
the blood pressure assessment so obtained has a superior
prognostic value [12-15]. Home blood pressure may also
have some positive effect on therapeutic adherence, though
evidence on this aspect is controversial, with some studies
showing a clear benefit and others showing no advantage
[16-19]. Lack of definite evidence might be attributed to
the limited number of studies performed so far, and to the
heterogeneity of the methodologies employed to assess and
quantify patients’ compliance with treatment in the differ-
ent trials [16-19].
Screening for eligibility:
Either gender (18 - 74 years)
Treated or untreated arterial hypertension 
(office + day-time ambulatory BP) 
Metabolic syndrome (ATP-III)




















Primary end-point: rate of day-time blood 
pressure normalization  (<135/85 mmHg)
Figure 1 Flow chart of the TELEBPMET study design. ATP, Adult
Treatment Panel; BP, Blood pressure; CM, Conventional
management; HBPT, Home blood pressure telemonitoring; W, Week.
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blood pressure telemonitoring (HBPT), defined as home
blood pressure monitoring coupled with telematic data
transmission to the doctor and real-time feedback on
patient’s status, may improve blood pressure control and
compliance to treatment, and may help in optimizing
the patient’s therapeutic regimen [20,21].
Although HBPT may in particular be of great advan-
tage for those patients requiring a closer follow-up, as in
the case of high-risk hypertensive patients, at the mo-
ment it has not yet been clarified whether this approach
may actually improve blood pressure control and adher-
ence and persistence to antihypertensive drug treatment
also in this category of hypertensive patients.
Methods
Study objectives
The study aims at investigating whether in high-risk
patients with hypertension and metabolic syndrome, day-
time ambulatory blood pressure control over 48 weeks is
more effective when based on regular HBPT (intervention
group), through monthly automated blood pressure tele-
transmission and feedback to the patient by the doctor,
rather than when based only on periodic measurements
made by doctors in their office during quarterly visits
(conventional management (CM) control group). The main
study endpoint will be the assessment and comparison of
the rate of subjects achieving a daytime ambulatory blood
pressure normalization (average daytime blood pressure
<135/85 mmHg) in the two randomization groups (inter-
vention vs. control).
The study will also assess the psychological determi-
nants of adherence and persistence to drug therapy and
the influence of HBPT on such psychological factors, as
well as the impact of HBPT on additional clinical and
economic outcomes. These will include the number of
additional medical visits, direct costs of patient manage-
ment, number of drugs or drug combinations used to
achieve blood pressure control, the level of cardiovascular
risk, the degree of target organ damage and frequency of
cardiovascular events, and the regression of the metabolic
syndrome.
Study design
The study has an open label, parallel group, randomized,
controlled design. After 1 week of run-in, patients will
be randomized to two different arms: (1) intervention
group (HBPT), with automated teletransmission of home
blood pressure values to the Investigator, every month,
over the first 24 weeks, followed by manual transmission
of self-measured blood pressure data to the HBPT center
immediately before each office visit, with regular doctor’s
visit every 3 months, in the second 24 weeks (see below
for details); (2) control group (CM) managed only throughregular office visit every 3 months. A flow chart of the
study design is reported in Figure 1.
Study sites and population
This is an Italian, multicenter trial involving 12 Hyper-
tension Centers, of which seven are located in northern
Italy, two in central Italy, and three in southern Italy.
The study will be conducted according to Good Clinical
Practice guidelines and the Declaration of Helsinki. The
protocol will be approved by the Ethics Committees of
the centers involved.
The study will include hypertensive patients with meta-
bolic syndrome, who are at an increased risk of cardiovas-
cular events in the short term, and for whom adequate
blood pressure control and treatment adherence are clin-
ically relevant issues.
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patients have to comply with the following criteria:
(1) male or female gender and age between 18 and 74 years;
(2) untreated or treated, but uncontrolled, essential arterial
hypertension (office systolic blood pressure ≥140 mmHg
and/or diastolic blood pressure ≥90 mm mmHg plus
average daytime ambulatory systolic blood pressure ≥135
mmHg and/or average daytime diastolic blood pressure
≥85 mm Hg); (3) presence of metabolic syndrome accord-
ing to ATP-III criteria [22], namely occurrence of at least
two of the following four clinical conditions: abdominal
obesity (waist circumference ≥102 cm in men and ≥88
cm in women), raised triglycerides (≥150 mg/dL or under
specific treatment with fibrates or nicotinic acid), reduced
HDL cholesterol (<40 mg/dL in men and <50 mg/dL in
women or under specific treatment with fibrates or nico-
tinic acid), elevated fasting glucose (≥100 mg/dL or use of
medication for hyperglycemia).
Main exclusion criteria are: (1) secondary hypertension;
(2) renal or liver impairment; (3) severe autoimmune dis-
eases; (4) neoplasia; (5) atrial fibrillation, frequent ectopic
beats or severe conduction disturbances (second and third
degree atrio-ventricular block), which may make auto-
matic blood pressure measurement difficult or unreliable;
(6) an arm circumference >32 cm or <22 cm; (7) any other
condition that might compromise the patient’s partici-
pation in the study, including illiteracy and diseases pre-
venting the completion of questionnaires (for example,
myopia); (8) patients not able to follow study procedures.
Patients meeting inclusion criteria will be fully informed
about the study design and purposes and asked to give a
written informed consent, if willing to participate. After
obtaining the written informed consent, eligible patients
will be randomized to one of the two study arms.
Randomization
Randomization will be performed using a blocked random-
ization procedure (computerized random numbers), in order
to obtain equal numbers in each study arm. Patients will be
randomized to CM or HBPT (1:2). In order to prevent se-
lection bias, the allocation sequence will be concealed from
the Investigator enrolling and assessing patients in sequen-
tially numbered, opaque, and sealed envelopes.
Description of the intervention: HBPT
At the time of the randomization, patients assigned to
HBPT, will be equipped with an electronic blood pres-
sure measuring device and a wireless transmitting inter-
face. These devices will be kept at home until the end of
the study.
The patient will be adequately trained by the Investigator
on measurement procedures. Patients will be asked to self-
measure their blood pressure at home twice a day, using
a validated, automatic, electronic, oscillometric, upper armmonitor (A&D UA-767PC, A&D Company Ltd., Tokyo,
Japan) [23]. The device can store up to 126 blood pres-
sure measurements in its memory, is operated by non-
rechargeable batteries, and is equipped with a serial port
for interfacing with a personal computer or a transmis-
sion unit.
Two measurements, at a 2-min interval, will be taken
in the morning before going to work or before starting
daily activities (between 08:00 and 10:00), and two mea-
surements will be taken in the evening (between 18:00
and 22:00), for a minimum of 3 days a week. The mea-
surements have to be taken in a quiet environment, with
the patient in a relaxed, comfortable, sitting position for
at least 5 min before self-measurement.
After each measuring session and when not used for
measuring blood pressure, the blood pressure monitor
will be connected through a serial cable to a GPRS wire-
less interface (BluMed). During the first 24 weeks, the
transmitter will send blood pressure data every day to
the www.morepress.net website, (Biotechmed Ltd., Somma
Lombardo, Varese, Italy) where they will be analyzed and a
report will be generated and sent once a month via email
to the Investigator. A feedback on the status of patient’s
blood pressure control will also be visualized on the inter-
face display.
The wireless interface also comes with a button which
allows the patient to manually send the data to the HBPT
center whenever it is deemed necessary (for example, in
case of symptoms or very high blood pressure values), in-
dependently from the scheduled program. During the last
24 weeks of the follow-up no automatic data transmission
will be done, but the patient will be requested to manually
send to the HBPT center the self-measured blood pressure
data, immediately before each scheduled office visit.
A diagram of the telemonitoring web-based system is
shown in Figure 2.
Description of the control condition
In the CM or control group, blood pressure will be mea-
sured only during the office visit by the same automatic
device used by patients of the HBPT randomization group.
After 5 min sitting, automated blood pressure measure-
ments will be performed twice at a 2-min interval and the
average of the measurements will be calculated and used
as clinical reference.
Study procedures
Besides baseline screening and randomization visits (Visit
1 and 2), all the patients will be re-assessed at 4 weeks
(Visit 3), 12 weeks (Visit 4), 24 weeks (Visit 5), 36 weeks
(Visit 6), and 48 weeks (Visit 7) of follow-up. If the Investi-
gator deems it appropriate extra visits can be planned.
Figure 3 presents an overview of variables measured at
each time point of the study. All data collected during the
GPRS wireless interface (BluMed )
Patient at home
(A&D UA-767PC, automatic, electronic, oscillometric, upper arm blood pressure monitor) 
Serial cable
GPRS
https protocol (SSL certification)
webserver
Investigator
https protocol (SSL certification)
Feed
back
The MOREPRESS® HBPT web-
based system
Figure 2 The Morepress web-based telemedicine system used in the TELEBPMET Study. GPRS, General Packet Radio Service; HBPT, Home
blood pressure telemonitoring; SSL, Secure Sockets Layer.
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web-based electronic case report form (e-CRF) linked to
the telemedicine system.
The study includes a first visit at the Hypertension











Psychological tests (set 1) (***)




Figure 3 Timing and content of study assessments. ABPM, Ambulatory
pressure telemonitoring.is measured, the patient’s history gathered, a physical
examination performed. Laboratory tests useful for the
determination of the organ damage and cardiovascular
risk will be assessed as well. These tests include bio-
chemistry and urinalysis (plasma lipids, fasting glucose,1 2 3 4 5 6 7
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albumin/creatinine ratio on morning urine sample or
24-h microalbuminuria), an echocardiogram with deter-
mination of left ventricular mass, a carotid ultrasonog-
raphy for determination of intima-media thickness, a
fundoscopy, and an electrocardiogram (ECG). Waist
circumference will also be measured. A 24-h ambula-
tory blood pressure monitoring will be performed (see
below for details).
Within 1 week from Visit 1 those patients complying
with the inclusion criteria (that is, values of office sys-
tolic blood pressure ≥140 mmHg and/or office diastolic
blood pressure ≥90 mmHg plus daytime systolic blood
pressure ≥135 and/or daytime diastolic blood pressure
≥85 mmHg, plus presence of metabolic syndrome) will
be randomized to the CM group or to the HBPT group
(Visit 2).
During the same visit the patients will be adminis-
tered the following psychological tests: Medical Outcome
Survey Short-Form 36 (SF-36), Psychological General Well-
Being Index (PGWBI), Beck Depression Inventory (BDI),
Locus of Control (LoC), Self-Esteem Inventory (SEI), Ill-
ness Behaviour Questionnaire (IBQ) and Coping strategies
(COPE), forming set 1, and Trait Anxiety Inventory (STAY),
Type D Personality (TDP), Type A Personality (TAP), Tem-
perament and Character Inventory (TCI), forming set 2
[24-35]. In untreated patients an antihypertensive treatment
will be initiated. In treated patients, antihypertensive drug
treatment will be adjusted in order to improve blood pres-
sure control and possibly achieve office blood pressure
normalization (<140/90 mmHg) on the next visit.
Four weeks later (Visit 3) the patients will be visited
again by the Investigator and the medical therapy will be
adjusted on the basis of office blood pressure (target,
<140/90 mmHg) in the CM group or home blood pres-
sure (target, <135/85 mmHg) in the HBPT group. Office
blood pressure will still be measured by the Investigator
with the same automatic electronic instrument used for
self-measurement, in all patients, including those rando-
mized to HBPT. Additional visits are scheduled 12, 24,
36, and 48 weeks after randomization (Visits 4, 5, 6, and
7). During each of these visits office blood pressure will
be measured and antihypertensive medication will be
changed according to office (CM group) or home blood
pressure values (HBPT group). Drug treatment can also
be changed in the patients of the HBPT between the
scheduled visits, based on the home blood pressure re-
port monthly received and reviewed by the Investigator.
The same laboratory tests performed at screening visit
and a 24-h ambulatory blood pressure recording will be
repeated at Visits 5 and 7. During these two visits psy-
chological tests will also be administered, with the exclu-
sion of STAY, TDP, TAP, and TCI test, administered only
at Visit 2.Occurrence of adverse events, adherence to therapy
and concomitant therapies will be checked at all visits
during the trial. Evaluation of adherence to drug treat-
ment will be based on patient’s report on amount of pre-
scribed drug intake and on counting the quantity of
study medication taken by the patient, comparing this
datum with the quantity expected to be returned. The
Investigator will instruct each patient to bring back used
and unused drug blisters at each visit. The compliance
will be computed as the ratio between the number of
pills taken and the number of pills which should have
been taken, expressed as a percentage, and will then be
graded as follows: excellent (100% of prescribed pills
taken), good (80% to 99%), fair (40% to 79%), or poor
(<40%).
Ambulatory blood pressure monitoring
At Visit 1, and subsequently at Visit 5 and at final visit
(Visit 7) an ambulatory blood pressure monitoring will be
performed non-invasively over 24 h by an oscillometric
validated device [36,37]. Current Guidelines will be fol-
lowed for proper recording performance [38,39]. The mon-
itoring cuff will be wrapped around the non-dominant arm
and the patient will be asked to keep her/his arm still dur-
ing the automatic blood pressure measurements. The de-
vice will be programmed to measure blood pressure every
15 min during the whole 24 h. Each recording will start in
the morning, before 07:00 and 10:00, immediately after
office blood pressure assessment. Patients will then be sent
home, asked to resume normal life, and to come back 24 h
later for removal of the device.
Home blood pressure monitoring
The modality of self-blood pressure measurement at
home has been detailed in the previous sections. In the
HBPT group home blood pressure reports will be auto-
matically transmitted to the Investigator every month
for the first 12 weeks (from Visits 2 to 5). Based on these
reports, the Investigator will be allowed to adjust drug
treatment before the next visit or to schedule an extra
study visit. Starting from Visit 5 until the end of the
study (Visit 7), the patients randomized to HBPT will
continue to self-measure blood pressure at home, but
automatic transmission will be disabled and each patient
will be asked to manually send blood pressure data the
day immediately preceding the office visit at the Center.
These home blood pressure measurements will be reviewed
by the Investigator exclusively on Visits 6 and 7, and treat-
ment adjusted accordingly.
Psychological tests
With the aim to investigate the psychological impact of
HBPT clinical psychologists will assess psychological
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standardized questionnaires:
(1) SF-36: a generic tool for assessing the quality of life,
aiming at quantifying the impact of disease on
general health and on the psychological profile, for
the determination of the most characteristic aspects
affecting quality of life in relation to a standard
reference population [24]
(2) PGWBI: a tool for the assessment of psychological
wellbeing [25]
(3) BDI: this test can be considered as a standard
reference among the self-assessment scales. A key
feature of the scale is the precise definition of the
criteria for quantification, since every item
corresponds to a given level of severity. The scale is
the most specific self-assessment tool for
depression, exploring a narrow range of symptoms
by excluding those related to anxiety [26]
(4) LoC: this test measures the tendency to attribute
the causes of behavior to internal or external
conditions [27,28]
(5) SEI: this test measures the degree of self-esteem of
the patient [29]
(6) IBQ: this test measures the disease perception [30]
(7) COPE: the test is designed to be a measuring
instrument capable of assessing the more subtle
individual differences in coping. It is able to balance
the general trend of the subject with the current
response to the stressful situation. Due to its
characteristics, this test is suitable for studies aiming
at clarifying more thoroughly the possible influence
of personality aspects on adaptation [31]
In order to investigate the personality traits under-
lying the adherence behavior, clinical psychologists
will also assess the following psychological dimensions
only at Visit 2 by using the following standardized
questionnaires:
(1) STAY: this test assesses the degree of trait anxiety
severity [32]
(2) TDP: the test evaluates the presence of the
personality traits defined as being distressed [33]
(3) TAP: the test evaluates the presence of type A
personality traits [34]
(4) TCI: a questionnaire for the self-evaluation of
different personality characteristics, normal and
abnormal, which is based on an interpersonal theory
of personality [35]
All psychological questionnaires used in the study
are psychometrically validated and standardized on the
Italian population.Statistical analysis
Primary outcome measures
The primary study endpoints are (1) the percentage of
patients achieving daytime blood pressure normalization
(systolic blood pressure <135 mmhg and diastolic blood
pressure <85 mmhg) 24 weeks after randomization (visit
5); and (2) the percentage of patients achieving daytime
blood pressure normalization after 48 weeks (visit 7).
The primary outcomes will be separately assessed for
the HBPT and CM groups.
Secondary outcome measures
A series of psychological and clinical variables will be
used as secondary endpoints.
Scoring of the different psychological questionnaires
will be computed for the HBPT and CM groups and
compared between groups. They will be used to quantify
therapeutic adherence, and compared with evaluation of
compliance based on the patient’s report.
The following clinical endpoints will also be evaluated:
(1) the percentage of patients with office blood pressure
normalization (<140/90 mmHg) after 24 and 48 weeks;
(2) percentage of patients with home blood pressure
normalization (average <135/85 mmHg) after 24 and 48
weeks in the HBPT group; (3) changes in average 24-h
systolic and diastolic blood pressure after 24 and 48
weeks vs. baseline; (4) changes in office systolic and dia-
stolic blood pressure after 24 and 48 weeks vs. baseline;
(5) changes in average home systolic and diastolic blood
pressure after 24 and 48 weeks vs. baseline in the HBPT
group; (6) the number of antihypertensive drugs pre-
scribed after 24 and 48 weeks vs. baseline; (7) the num-
ber of office or phone visits after 24 and 48 weeks vs.
baseline; (8) direct costs of patient management, based
on additional medical visits and laboratory tests performed
between baseline and 24 and 48 weeks; (9) adherence to
treatment, as reported by the patient (the assessment of
adherence and persistence to therapy will also be done
indirectly, by evaluating adherence to the home blood
pressure monitoring program and by evaluation of the
psychological tests); (10) difference in target organ damage
score between baseline and week 24 and 48 of the study;
(11) difference in cardiovascular risk level between base-
line and week 24 and 48 of the study according to Heart
Score (ESH-ESC) and Framingham algorithm [40,41]; (12)
difference in the rate of cardiovascular events between
baseline and 24 and 48 weeks of follow-up; and (13) the
number of subjects showing regression of metabolic syn-
drome after 24 and 48 weeks from the randomization.
Sample size
The underlying study hypothesis is that the percentage of
subjects achieving daytime blood pressure normalization
will be 25% larger in the HBPT group. Using a two-tailed
Parati et al. Trials 2013, 14:22 Page 8 of 11
http://www.trialsjournal.com/content/14/1/22test with a 0.05 significance level and an 80% power, the
estimated number of patients to be randomized is 252 (in-
cluding a 25% drop-out rate), with 84 patients randomized
to CM and 168 to HBPT.
Planned statistical analyses
Analysis will be performed on patients valid for intention-
to-treat, defined as all subjects with at least one visit
during the randomized phase of the study and with
valid ambulatory blood pressure recordings at baseline,
after 24 and 48 weeks of follow-up even in the presence
of protocol violations. A confirmatory analysis on the per-
protocol (patients who have successfully completed the
study without major protocol violations) is also foreseen.
The demographic and clinical characteristics of the
two study groups will be compared at baseline by ana-
lysis of variance (continuous variables) or by Mantel-
Haenszel Chi-square test (categorical variables), in order
to verify the between-group homogeneity at randomization.
The same tests will be used to compare primary and
secondary study endpoints between the CM and HBPT
groups. If deemed necessary, in addition to the univariate
approaches, multivariate analysis methods will be used.
The type and frequency of drug-related adverse events
will be reported for each randomization group. The ab-
solute rate of adverse events will be compared between
groups using the Chi-square test.
The minimum level of statistical significance will be
set at P <0.05.
Discussion
This article describes the background, objectives, and
design of a randomized controlled trial that will test the
superiority of HBPT as compared to CM in improving
blood pressure control in high-risk hypertensive patients
with metabolic syndrome. Our study will help adding
further evidence on the effectiveness of treatment decision
of hypertension based on home blood pressure monitoring
or HBPT. Findings from previous studies are controversial
to this regard. In the THOP (Treatment of Hypertension
based on home or Office blood Pressure) trial [42], antihy-
pertensive drug treatment in hypertensive patients with an
office diastolic blood pressure ≥95 mmHg, was adjusted in
a stepwise fashion based on either the self-measured dia-
stolic blood pressure at home or on readings taken at the
doctor’s office. Adjustment of antihypertensive treatment
based on home blood pressure led to less intensive drug
treatment and marginally lower costs, but also to less blood
pressure control, with no differences in quality of life and
target organ damage. Similarly, in the HOMERUS (Home
versus Office blood pressure MEasurements: Reduction of
Unnecessary treatment Study) trial [43] self-measurement
of blood pressure at home led to less medication use
than office blood pressure measurement without leadingto significant differences in office blood pressure values or
target organ damage. However, in both the aforemen-
tioned studies, the target value for home blood pressure
was the same as that for office blood pressure and higher
than that recommended by current guidelines [9,39]. More
recently, the HOMED-BP (Hypertension Objective Treat-
ment Based on Measurement by Electrical Devices of Blood
Pressure) [44] proved that adjusting antihypertensive drug
treatment on the basis of blood pressure values collected
through HBPT is feasible and effective for maintaining an
optimal target blood pressure level and optimal antihyper-
tensive medication. This is in line with a systematic meta-
analysis of randomized controlled studies, which demon-
strated the superiority of HBPT vs. usual care in improving
blood pressure control in either low- or high-risk hyperten-
sive patients [21].
Secondarily, the trial will investigate and compare be-
tween randomization groups personality traits predictive of
adherence. This will be useful to identify possible psycho-
logical determinants of adherence to antihypertensive treat-
ment, also relating them to blood pressure response to
antihypertensive treatment in daily life conditions. Poor ad-
herence to treatment remains one of the major limitations
in the management of hypertension: it may cause poor
blood pressure control and may contribute to increased
morbidity, mortality, and costs [45,46].
Previous studies have shown that persistence with
antihypertensive therapy decreases with time: discon-
tinuation rates vary from 22% to 50% of patients during
the first year after treatment initiation [47-50]. There-
fore, improving adherence to treatment remains a major
challenge for the treating physician. Use of blood pres-
sure telemonitoring technique, which might help in im-
proving blood pressure control and adherence, together
with quantification and definition of the psychological
trait of the hypertensive patient, might help identifying
features of high-risk hypertensive patients and increase
the chance of successful treatment.
The study will also evaluate the impact of HBPT on
additional medical and economic outcomes, which might
help in unmasking possible additional advantages of this
technique in high-risk hypertensive patients, on a rela-
tively long-term follow-up.
Before drawing the conclusions we must acknowledge
that the study protocol suffers from some potential meth-
odological limitations. First, allocation of patients to one of
the two study groups will be concealed from the Investiga-
tor by means of sequentially numbered, opaque, and sealed
envelopes. We acknowledge that this approach may intro-
duce a bias and that central computerized randomization
would be preferred. However, web-based randomization
was not possible due to limited availability of continu-
ous Internet connection in some centers and telephone
interactive voice response services could not be afforded
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adherence will be based on both self-report of patients
and on manual pill count by the Investigator. This meth-
odology might be imprecise. However, adherence is not
the primary study endpoint, and though the use of elec-
tronic pill-box monitoring was taken into account at the
time of study planning and designing, we opted out of this
choice because the device was too expensive and its man-
agement too complex for the study purposes.
Conclusions
At the moment no studies have assessed the impact of
HBPT and of the quantification of patient’s psychological
characteristics on improvement of blood pressure con-
trol and adherence to antihypertensive treatment. The
TELEBPMET Study will show whether this approach is
effective in management of hypertensive patients with
metabolic syndrome. It will also provide a comprehensive
understanding of the psychological determinants of medi-
cation adherence and blood pressure control in high-risk
patients with hypertension.
Trial status
The TELEBPMET study trial was conceived and designed
in 2008. At the time this manuscript was submitted full
approval by the Medical Ethics Committee has been
obtained for all centers and recruitment was started. The
patients’ follow-up is currently ongoing.
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